Warby Parker, Inc. (WRBY)
NYSEHealth CareSpecialty RetailSnapshot 2026-09-04
NYSEHealth CareSpecialty RetailSnapshot 2026-09-04
Warn: Primary pillar under pressure — Achieve 10% to 12% revenue growth in 2026: Q2 FY26 YoY +9.8% vs 10-12% target; FY26 guide $959-976M.
Warby Parker plans to open 50 new stores in 2026. Revenue should grow 10% to 12% this year. The company has a $100 million share buyback program. Profitability is stable and the brand is strong.
Insider stock sales raise doubts about leadership confidence. Revenue growth could slow below 10%. The high price-to-earnings ratio risks a valuation drop.
The price is about 12% above our fair value near $25. Analysts expect 18% revenue growth, which is optimistic versus our 10%-12% target.
Breaks if: YoY revenue growth falls below 8% in 2026
Target net revenue growth of approximately 10% to 12% for the full year 2026 compared to 2025.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth. The current thesis state is intact, supported by strong recent financial performance, but it faces challenges due to elevated risks and expensive valuation.
The market seems to assume a high level of performance given the expensive valuation compared to peers. There is an expectations gap, indicating that the current price may not fully reflect the risks and uncertainties ahead.
Management is on track to achieve its revenue growth target of 10% to 12% for 2026, supported by recent strong financial results. However, there is a low probability of missing guidance, though past performance shows a history of misses that could affect investor sentiment.
The thesis hinges on the company's ability to launch the Intelligent Eyewear product line successfully and maintain revenue growth. Additionally, external factors like the performance of sector bellwether PETS and broader economic conditions will play a crucial role.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company missed revenue estimates recently. This suggests potential growth issues ahead. However, strong revenue growth supports the goal of 10-12% growth. The launch of Intelligent Eyewear aligns with management's product objectives. An underwhelming launch may hinder this product line's success.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $223.8 million in 2025-Q1 to $235.5 million in 2026-Q2, and full year 2026 guidance targets $959 to $976 million, about 10% to 12% growth over 2025's $871 million. The trajectory is delivering consistent revenue growth aligned with management's stated target.
“Reaffirming guidance: Net revenue of $959 to $976 million, approx. 10% to 12% growth versus 2025.”
“Reaffirming guidance: Net revenue of $959 to $976 million, approx. 10% to 12% growth versus 2025.”
“Providing guidance: Net revenue of $959 to $976 million, approx. 10% to 12% growth versus 2025.”
Breaks if: repurchase program is canceled or less than $50 million executed
Warby Parker announced a $100 million share repurchase program to enhance shareholder value.
Breaks if: fewer than 40 stores opened by end of 2026
Expand retail footprint by opening 50 new stores during the 2026 fiscal year.
Stated as a priority in 3 of last 3 quarters. Management opened 15 net new stores in 2026-Q2, reaching 352 stores, progressing toward the 50 new store openings target for 2026. The trajectory shows active expansion consistent with the stated goal.
“Guidance includes 50 new store openings in 2026.”
“Reaffirming guidance of 50 new store openings in 2026.”
“Guidance includes 50 new store openings.”
In the next 1 to 3 years, WRBY's performance will depend on management execution and market conditions. Not investment advice.